Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

被引:339
|
作者
Jönhagen, ME
Nordberg, A
Amberla, K
Bäckman, L
Ebendal, T
Meyerson, B
Olson, L
Seiger, Å
Shigeta, M
Theodorsson, E
Viitanen, M
Winblad, B
Wahlund, LO
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Clin Neurosci & Family Med, Div Geriatr Med, S-14186 Huddinge, Sweden
[2] Uppsala Univ, Biomed Ctr, Dept Dev Neurosci, Uppsala, Sweden
[3] Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-10401 Stockholm, Sweden
[4] Karolinska Inst, Dept Neurosci, S-10401 Stockholm, Sweden
[5] Linkoping Univ Hosp, Dept Clin Chem, S-58185 Linkoping, Sweden
[6] Jikei Univ, Sch Med, Dept Psychiat, Tokyo, Japan
关键词
nerve growth factor; Alzheimer's disease; cognitive deficits; electroencephalography; positron emission tomography; pain; weight loss; nicotinic receptors;
D O I
10.1159/000017069
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Nerve growth factor (NGF) is important for the survival and maintenance of central cholinergic neurons, a signalling system impaired in Alzheimer's disease, We have treated 3 patients with Alzheimer's disease with a total of 6.6 mg NGF administered continuously into the lateral cerebral ventricle for 3 months in the first 2 patients and a total of 0.55 mg for 3 shorter periods in the third patient, The patients were extensively evaluated with clinical, neuropsychological, neurophysiological and neuroradiological techniques, Three months after the NGF treatment ended, a significant increase in nicotine binding was found in several brain areas in the first 2 patients and in the hippocampus in the third patient as studied by positron emission tomography. A clear cognitive amelioration could not be demonstrated, although a few neuropsychology tests showed slight improvements, The amount of slow-wave cortical activity as studied by electroencephalography was reduced in the first 2 patients. Two negative side effects occurred with NGF treatment: first, a dull, constant back pain was observed in all 3 patients, which in 1 patient was aggravated by axial loading resulting in sharp, shooting pain of short duration, When stopping the NGF infusion, the pain disappeared within a couple of days, Reducing the dose of NGF lessened the pain. Secondly, a marked weight reduction during the infusion with a clear weight gain after ending the infusion was seen in the first 2 patients. We conclude from this limited trial that, while long-term intracerebroventricular NGF administration may cause certain potentially beneficial effects, the intraventricular route of administration is also associated with negative side effects that appear to outweigh the positive effects of the present protocol, Alternative routes of administration, and/or lower doses of NGF, perhaps combined with low doses of other neurotrophic factors, may shift this balance in favor of positive effects.
引用
收藏
页码:246 / 257
页数:12
相关论文
共 50 条
  • [41] Alzheimer's disease animal models induced by continuous infusion of beta-amyloid protein and anti-nerve growth factor antibody
    Nabeshima, T
    Itoh, A
    [J]. REVIEWS ON HETEROATOM CHEMISTRY, 1997, 16 : 229 - 255
  • [42] Nerve growth factor in Behcet's disease
    Accorinti, M
    Bruscolini, A
    Lambiase, A
    Speranza, S
    Bonini, S
    Pivetti-Pezzi, P
    [J]. ADAMANTIADES-BEHCET'S DISEASE, 2003, 528 : 283 - 285
  • [43] A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer's Disease
    Mitra, Sumonto
    Gera, Ruchi
    Linderoth, Bengt
    Lind, Goran
    Wahlberg, Lars
    Almqvist, Per
    Behbahani, Homira
    Eriksdotter, Maria
    [J]. RECENT ADVANCES IN NGF AND RELATED MOLECULES: THE CONTINUUM OF THE NGF SAGA, 2021, 1331 : 167 - 191
  • [44] Determination of truncated nerve growth factor receptors as a biological marker for diagnosis of Alzheimer's disease
    Mesripour, M.
    Nazarian, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 48 - 48
  • [45] HYPOPHAGIA IS INDUCED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF NERVE GROWTH-FACTOR
    WILLIAMS, LR
    [J]. EXPERIMENTAL NEUROLOGY, 1991, 113 (01) : 31 - 37
  • [46] IS ALZHEIMER-DISEASE CAUSED BY LACK OF NERVE GROWTH-FACTOR
    HEFTI, F
    [J]. ANNALS OF NEUROLOGY, 1983, 13 (01) : 109 - 110
  • [47] Evoked potentials in the sacred baboon:: Long-term follow-up of intracerebroventricular infusion of nerve growth factor
    Baez, MM
    Morales, L
    Fernández, CI
    Cabrera, I
    González, O
    Padilla, E
    Zaldívar, M
    [J]. REVISTA DE NEUROLOGIA, 1999, 28 (07) : 665 - 668
  • [48] Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease
    Ubhi, Kiren
    Rockenstein, Edward
    Vazquez-Roque, Ruben
    Mante, Michael
    Inglis, Chandra
    Patrick, Christina
    Adame, Anthony
    Fahnestock, Margaret
    Doppler, Edith
    Novak, Philip
    Moessler, Herbert
    Masliah, Eliezer
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2013, 91 (02) : 167 - 177
  • [49] Connective tissue growth factor in Alzheimer's disease
    Ueberham, U
    Ueberham, E
    Gruschka, H
    Arendt, T
    [J]. NEUROSCIENCE, 2003, 116 (01) : 1 - 6
  • [50] Nerve growth factor treatment in Alzheimer's disease: EEG changes and relation to FDG-PET
    Eyjolfsdottir, H.
    Eriksdotter, M.
    Almqvist, P.
    Almqvist, O.
    Kadir, A.
    Karami, A.
    Lind, G.
    Linderoth, B.
    Wahlberg, L.
    Seiger, A.
    Jelic, V.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 110 - 110